Overcoming tumor resistance mechanisms in CAR-NK cell therapy

Overcoming tumor resistance mechanisms in CAR-NK cell therapy

Despite the impressive results of autologous CAR-T cell therapy in refractory B lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost-effective approach with no signs of severe toxicities as described for CAR-T cells. Permanently scrutinized for its efficacy, recent...

Full description

Bibliographic Details
Main Authors: Antonio Valeri, Almudena García-Ortiz, Eva Castellano, Laura Córdoba, Elena Maroto-Martín, Jessica Encinas, Alejandra Leivas, Paula Río, Joaquín Martínez-López
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor (CAR)
CAR NK cells
hematologic tumor
genome editing
CRISPR/Cas9
tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.953849/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.953849/full

Similar Items